Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

J Cancer Res Clin Oncol · 2013 · PMC3678021 · PMID 23604446

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.2500

boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)

Patients with nonluminal/HER2+ tumors (HER2+, ER−, PgR−) showed a trend toward a worse DFS ( P = 0.06; HR = 1.82, 95 % CI 0.96–3.45) and CSS ( P = 0.053; HR = 2.55, 95 % CI 0.99–6.58, Fig. 2 ) compared to those with luminal B/HER2+.

also in 53,322 other papers

a trend toward significanceP = 0.25not close (p > 0.1)

However, in the molecular subclass of nonluminal/HER2+ (HER2+, ER−, PgR−) pCR/is was predictive of better outcome in terms of DFS ( P = 0.04; HR = 0.38, 95 % CI 0.15–0.96) with a trend toward significance for CSS ( P = 0.25; HR = 0.48, 95 % CI 0.14–1.66, Fig. 1 ).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.